Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Modulation During Palynziq Treatment in Adults With PKU
NCT07477691Phase 4Recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of methotrexate in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
methotrexate
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07477691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477691.